Amycretin Shows Up to 24% Weight Loss in Early Trials, With Added Blood Sugar Benefits: Study
The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with weekly injections and 13% with daily oral doses—in early trials, while also improving blood sugar control. Mild to moderate gastrointestinal side effects were reported.
As is now well known, obesity and excess adiposity is a global health issue, burdening people with multiple comorbidities such as type 2 diabetes, cardiovascular disease, musculoskeletal diseases, cancer, and sleep apnoea.
The treatment of obesity and its comorbidities has been revolutionised in the past 5–10 years with the introduction of GLP-1 receptor monoagonists such as semaglutide and, more recently, the GLP-1 and glucose-dependent insulinotropic peptide receptor multiagonist tirzepatide. The pharmaceutical industry has been actively exploring other multiagonist strategies in which GLP-1 receptor agonism is combined with complementary satiety or metabolic hormone activities to obtain enhanced efficacy, whether for weight loss, appetite suppression, or other metabolic effects.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.